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CObjectives: About 190,000 Germans experience a myocardial infarc-
tion each year. Of these, 25%may be eligible for an implantable cardio-
verter defibrillator (ICD) due to low left ventricular ejection fraction.
Given the high costs of implantation, the purpose of this study was to
assess the cost-effectiveness of ICDs compared to conventional ther-
apy in patients with an ejection fraction 30% or less after MI in
Germany.Methods: The economic evaluationwas performed from the
erspective of the German statutory health insurance. To simulate
osts and effectiveness over lifetime, a Markovmodel was constructed
ith seven health states. The model was based on 8-year follow-up
ata for ICD implantation aftermyocardial infarction (MADIT II), which
as published recently. Results: The analysis shows that ICD implan-
ation compared to conventional therapy in patients fulfillingMADIT-II O
c
f
c
s
G
l
edica
al So
doi:10.1016/j.jval.2011.02.1180riteria has a cost-effectiveness ratio of €44,736 per quality-adjusted
ife year gained. If every patient insured by the statutory health insur-
nce and fulfilling the MADIT-II criteria would receive an ICD, the
odel suggests expenditures between €173 million and €1.7 billion per
ear. Conclusions: ICD therapy cannot be considered clearly cost-ef-
ective when compared to many well-accepted interventions. If policy
akers decide to reimburse ICDs in the MADIT-II population, they will
eed to either raise premiums or abandon coverage for other currently
unded medical interventions.
eywords: decision analysis model, economic evaluation, heart failure,
uality-adjusted life years.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
About 190,000Germans experience amyocardial infarction (MI) each
year [1]. After MI the myocardial muscle is weakened and left-ven-
tricular systolicdysfunction (LVSD) canoccur.More thanone-thirdof
patients with MI may develop LVSD during hospitalization [2]. Pa-
tients with LVSD may be asymptomatic for some time until they
develop symptoms of heart failure. LVSD or heart failure can lead to
ventricular fibrillation and sudden cardiac death (SCD).
Implantable cardioverter defibrillators (ICDs) were developed to
prevent SCD in patients with LVSD or heart failure. They are recom-
mended inguidelinesof theGermanCardiacSociety forpatientswho
have experienced MI and have a left ventricular ejection fraction
(LVEF) of 30% or less [3]. ICD therapy is expensive: in Germany the
implantation alone costs approximately €17,000 [4]. Unlike other in-
terventions, ICD therapy does not reduce the costs of sickness. ICDs
neither cure the disease nor do they improve quality of life. They
prevent SCD and thus have solely a life-prolonging effect.
Cost-effectiveness analyses (CEAs) on ICD therapy for LVSD
after MI exist for the United States, England, and Brazil [5-9] but
ot so far for Germany. Furthermore, no CEA has yet considered
-year follow-up data for ICD implantation after MI, which were
ublished recently [10].
* Address correspondence to: Afschin Gandjour, Pennington Biom
Suite G3047, Baton Rouge, LA 70808, USA.
E-mail: afschin.gandjour@pbrc.edu.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.This study therefore evaluated the cost-effectiveness of ICDs
ompared to conventional therapy in patients with an ejection
raction 30%or less afterMI inGermany, based on 8-year follow-up
linical data [10]. Given the high prevalence of LVSD after MI, this
tudy also estimated the annual population cost of ICD therapy in
ermany. Currently, only one-third of the German patient popu-
ation receives ICDs as recommended [11].
Methods
The economic evaluationwas performed from the perspective of the
German statutory health insurance (SHI), which covers 89% of the
German population [12]. The economic evaluation is a cost-utility
analysis using quality adjusted life years (QALYs) as a health out-
come. QALYs are the product of life years and a measure of health-
relatedquality of life (preferenceweightor score). Preferenceweights
are anchored on a scale from zero to one, where zero and one repre-
sent death and full health, respectively. The incremental cost-effec-
tiveness ratio (ICER) was determined by dividing the incremental
costs (i.e., additional costs) of ICDs compared to conventional ther-
apy by the incremental (i.e., additional) QALYs gained. The annual
population cost was calculated by multiplying incremental costs by
the annual incidence of SHI patientswith a LVEF 30%or less afterMI.
l Research Center/Louisiana State University, 6400 Perkins Road,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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813V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 2 – 8 1 7To simulate costs and effectiveness over lifetime, a Markov model
wasconstructed.AMarkovmodel isan iterativeprocesswherepatients
stay in one cycle (i.e., a defined health state) for a certain time (here 1
year) and thenmake a transition to another cycle. For the ICD arm the
following health states were considered (Fig. 1): ICD implantations,
CD removal, lead problem, nonfatal infection, hospitalization for
eart failure, and death. For the non-ICD armwe included conven-
ional therapy, hospitalization for heart failure, and death as
ealth states.
Markovmodels are useful when a decision problem involves risk
hat is continuous over time,when the timing of events is important,
nd when important events may happen more than once. A half-
ycle correction was used to allow for transition events occurring
idway through each 12-month cycle. A cycle length of 1 year was
hosen because most data were given in units per year. The Markov
odel included32cycles todeterminecostsandeffectsover lifetime.
fter 32 cycles theproportionof patients still alivewas less than0.1%
n both arms.
Data sources
A PubMed search for randomized controlled trials with the MeSH
terms “defibrillators, implantable” AND “myocardial infarction”
yielded 45 hits (January 2, 2010). Thirteen of these were directly re-
lated to the Multicenter Automatic Defibrillator Implantation Trial II
(MADIT II) [13], a large randomized trial that was conducted in 71 US
andfive European centers (includingGermany) anddesigned to eval-
uate the effectiveness of ICDs in patients with a history of MI of at
least 1month.Wedecided onMADIT II as the source of our effective-
ness data for several reasons: the largenumber of patients (1233), the
availability of long-term follow-up data (8 years), the relatively high
quality of the study design, and primary prevention of SCD as the
object of the study. The target population for the study consisted of
patients (men and women) with an ejection fraction 30% or less at
least 1 month after MI at an average age of 64 years. The American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines [14] and the GermanCardiac Society [3] also refer
toMADIT II for their recommendation touse ICDs inpost-MIpatients
with an LVEF 30% or less. Other trials were excluded because they
were too small [15] or included non-MI patients [16,17].
TheMADIT II reported a hazard ratio ofmortality of 0.59 and 0.71
at 4 and 8 years, respectively [10]. Based on these hazard ratios prob-
ability of survival at time twas calculated as follows [18]:
Fig. 1 – Schematic representation of the Markov model for the
implantable cardioverter-defibrillator (ICD) group. Ellipses
indicate health states, arrows show transitions. HF, heart
failure.SICD(t) Sno ICD(t)
HRwhere S  survival probability, and HR  hazard ratio of ICD im-
lantation versus no implantation.
Probabilities of nonfatal infections requiring surgical inter-
ention after ICD implantation as well as the probability of ICD
emoval were also based on MADIT II [13]. For the latter we
xcluded explanations due to heart transplantation as the de-
ision whether or not to transplant after ICD implantation re-
uires an independent evaluation.
The annual probability of ICD failure and need for a new battery
as determined based on Swiss data (n  644) [19]. For the first 2
ears after implantationweassumedno failures [19]. For the remain-
ng life time we converted the 6-year failure probability into an an-
ual failure probability by calculating the annual hazard rate [20].
The probability of hospitalization for heart failure was also
ased onMADIT II [21]. Follow-up data across 3 years showed that
atients assigned to the ICD arm were hospitalized more often
ecause of heart failure than patients in the non-ICD arm. We
onservatively assumed that this increase in hospitalization rate
ould continue beyond the 3-year follow-up period.
Costs of ICD implantation and battery replacement were calcu-
atedbasedon theaverage reimbursement rateofhospitals acrossall
erman states [4], the proportion of single versus dual chamber de-
brillators [13], and the proportion of implantations with versus
ithout major complications or comorbidities [4]. Hospital reim-
ursement rates cover, among others, physician payments, drugs,
nd imaging. Copayments by patients were subtracted.
Costs of outpatient follow-up after ICD implantation were calcu-
ated by assuming two annual cardiologist visits and checks. Except
or these follow-up costs, we assumed that costs of outpatient care
nd drugs would be the same in both arms. InMADIT II [13] both the
ICD arm and the comparator received conventional therapy, includ-
ing medications such as amiodarone, angiotensin converting en-
zyme inhibitors, and beta blockers. We also assumed that patients
would not have to pay out-of-pocket for outpatient follow-up visits
as the quarterly fee for physician visits would be paid anyway. Be-
cause this study held the perspective of the SHI, costs of hospital
infrastructure (building and equipment maintenance), nursing care,
and travel of informal caregivers were not considered.
The QALY weight for heart failure was based on a British study
conducted in 2002, included 313 patients, and used the EQ-5D
questionnaire [6]. Although ICD recipients may experience fear,
anxiety, depression, and shocks following ICD implantation, a sig-
nificant decrease in quality of life for the average ICD patient has
not been shown yet [6,22,23].
For the population cost analysis we estimated the number of
eligible patients in the German SHI population. For the high esti-
mate we assumed—based on Danish trial data from the 1990s—
that 25% of patients with MI have a LVEF 0.30 or less [24]. This is a
high estimate because medical care after MI has improved since
then [25]. As a low estimateweused 2.5% based on aGerman study
with 10.612 post-MI patients [11]. This study population included
younger and better-managed post-MI patients.
The values for the input variables are listed in Table 1. All costs
were inflated to 2009 euros using the German consumer price index.
Extrapolating survival effects
Because MADIT II had a follow-up period of 8 years and no
longer-term data on ICDs in the primary prevention of SCDwere
available from other trials, we extrapolated survival data to as-
sess lifetime costs and effects. The annual mortality rate with-
out ICDs was determined by adding the increase of the death
rate for other causes (using the mortality table of the German
Federal Statistic Office [26]) to the 1-year mortality rate without
ICD at age 72 years (i.e., the last year for which MADIT-II data
were available).
For projecting the hazard ratio of ICD therapy we had two sce-
narios. In the base-case the hazard ratio of ICD therapy (fromYear
814 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 2 – 8 1 75 to Year 8) and thus the life-prolonging effect stays constant over
time. In a secondary scenario the hazard ratio increases linearly
after 8 years and becomes one (no effect) after 12 years.
Sensitivity analysis
To address uncertainty around the mean incremental cost-effec-
tiveness ratio, we conducted univariate sensitivity analyses,
where we varied one variable at a time while keeping all other
variables constant at their mean or base-case value. We ran the
analyses based on the upper and lower boundaries of the 95%
confidence interval of the mean (Table 1). To assess how a simul-
taneous change of several variables affects the cost-effectiveness
ratio, we performed a Monte-Carlo simulation, a type of multivar-
iate sensitivity analysis. This technique runs a large number of
simulations (here 1000) by repeatedly drawing samples fromprob-
ability distributions of input variables. Thus, it provides a proba-
bility distribution for the output variables; that is, incremental
costs, incremental effectiveness, and incremental cost-effective-
ness ratios. Probabilities and the QALY weight for heart failure
were assumed to follow a beta distribution because they are re-
stricted to take on values between zero and one (Table 1). The
hazard ratio with ICD was assumed to follow normal distribution
after logarithmic transformation. For the base-case analysis, we
discounted both costs and effects at an annual rate of 3% [30]. All
calculations were done in Microsoft Excel 2007 (Microsoft Corpo-
ration, Redmond, WA).
Table 1 – Base-case values and ranges used in the decision
Input variable
Effectiveness/safety data
Mortality rate without ICD at age 72
Hazard ratio with ICD (0 – 4 y after implantation)
Hazard ratio with ICD (5 – 8 y after implantation)
Increase in annual mortality
Annual probability of hospitalization for HF
Probability of lead problems requiring surgical intervention
after ICD implantation
Probability of nonfatal infections requiring surgical
intervention after ICD implantation
Probability of ICD removal
Annual probability of ICD failure (post year 2)
Cost data
Cost of implantation
Cost of battery replacement
Cost of revision due to lead problems or nonfatal infections
Cost of explantation
Annual follow-up costs after implantation
Cost of hospitalization for HF
Annual cost of HF
Other data
Preference weight for all patients
Incidence of LVEF  30% one year after MI in Germany
HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, le
* 95% confidence interval.
Table 2 – Base-case (quality-adjusted) life expectancy and
Life expectancy
(undiscounted)
Life expectancy
(discounted)
ICD implantation 7.2 8.5
Conventional therapy 5.8 6.7ICD, implantable cardioverter defibrillator; QALY, quality-adjusted life yeaGiven that the interpretation of negative ICERs is ambiguous,
we transformed ICERs into net monetary benefits (NMB) [31] using
the following equation:
NMBEC
where
 maximum willingness-to-pay
C  incremental costs
E  incremental QALYs.
The decision rule we used was to adopt the intervention in
question if NMB was greater than zero. Given that the appropri-
ate value of  is unknown,  was varied from €0 to €100,000. We
generated a cost-effectiveness acceptability curve based on the
distribution of NMB for each . A cost-effectiveness acceptabil-
ity curve allows a decision-maker to consider if ICD implanta-
tion is cost-effective in relation to the maximum amount a de-
cision maker is willing to pay for a QALY. At each ceiling value
for the willingness to pay for a QALY, the cost-effectiveness
acceptability curve shows the probability that the treatment is
cost-effective.
Results
Results are listed in Table 2. The ICER of ICD implantation com-
pared to conventional therapy in patients fulfilling MADIT-II
del. All costs are in 2009 euros.
Mean (range) Source
13.6% [10]
0.59 (0.47–0.73)* [10]
0.71 (0.52–0.96)* [10]
By age [26] (data from 2006/08)
By age and treatment group [21]
1.8% (1.0–3.0)* [13]
0.7% (0.3–1.6)* [13]
0.53% (0.51–0.54)* [13]
15% (11–18)* [19]
€17,152 [4]
€14,201 [4]
€3447 [4]
€1795 [4]
€98 [27]
€2727 [4]
€9701 [24,28]
0.74 (0.71–0.77)* [6]
47 500 (4750) [1,11,22,29]
tricular ejection fraction; MI, myocardial infarction.
me costs for ICD implantation vs conventional therapy.
ALYs
counted)
Costs
(discounted)
Incremental cost-effectiveness
ratio (cost/QALY)
5.3 101,860 44,736
4.3 56,280mo
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815V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 2 – 8 1 7criteria in Germany is €44,736 per QALY gained and €33,105 per
ife year gained. If every patient insured by the SHI and fulfilling
he MADIT-II criteria would receive an ICD, the model suggests
xpenditures between €173 million and €1.7 billion per year (de-
ending on the proportion of patients with MI who have a
VEF  0.30).
In the univariate sensitivity analysis, the variablewith the larg-
st influence on incremental costs and effectiveness was the haz-
rd ratio of ICD therapy from Year 5 to Year 8 (Table 3). Figure 2
hows results of the Monte Carlo simulation with 998 out of 1000
eplications yielding both a cost and QALY increase. Based on this
imulation we derived a cost-effectiveness acceptability curve as
hown in Figure 3.
Table 3 – Univariate sensitivity analyses.
Incre
Hazard ratio with ICD (0–4 y after implantation)
Lower limit (0.47)
Upper limit (0.73)
Hazard ratio with ICD (5–8 y after implantation)
Upper limit (0.52)
Upper limit (0.96)
Annual probability of hospitalization for HF
Lower limit
Upper limit
Probability of lead problems requiring surgical
intervention after ICD implantation
Lower limit (1.0%)
Upper limit (3.0%)
Probability of nonfatal infections requiring surgical
intervention after ICD implantation
Lower limit (0.3%)
Upper limit (1.6%)
Annual probability of ICD failure
Lower limit (11%)
Upper limit (18%)
Probability of ICD removal
Lower limit (0.51%)
Upper limit (0.54%)
Preference weight for all patients
Lower limit (0.71)
Upper limit (0.77)
HF, heart failure; ICD, implantable cardioverter defibrillator; ICER, in
Fig. 2 – Cost-effectiveness plane showing 1000 replications
from a distribution of cost and quality-adjusted life year
(QALY) differences (implantable cardioverter defibrillator
[ICD] vs conventional therapy).In the secondary scenario where the hazard ratio increases
inearly after 8 years and becomes one (no effect) after 12 years the
CER is €63,190 per QALY gained and total population cost is €1.5
illion per year.
Discussion
This article presents the first CEA of ICD therapy for LVSD after MI
based on long-term data of MADIT II over 8 years. It shows that ICD
therapy cannot be considered clearly cost-effective when compared
to many well-accepted interventions [32], but still may be regarded
acceptable. Main reasons for this result are high costs of initial ICD
implantation as well as lack of a morbidity-reducing effect.
Recently the Institute for Quality and Efficiency in Health Care
(Institut für Qualität undWirtschaftlichkeit imGesundheitswesen
tal costs Incremental QALYs gained ICER
81 1.1 42,783
27 0.9 47,300
94 1.8 32,455
20 0.3 103,120
76 1.0 43,162
83 1.0 46,310
52 1.0 44,709
20 1.0 44,776
66 1.0 44,723
10 1.0 44,766
49 1.0 41,958
10 1.0 47,514
79 1.0 44,736
80 1.0 44,736
80 1.0 46,626
80 1.1 42,993
ntal cost effectiveness ratio; QALY, quality-adjusted life year.
Fig. 3 – Cost-effectiveness acceptability curve showing the
probability that implantable cardioverter defibrillatorsmen
46,8
44,1
59,7
33,6
43,9
47,1
45,5
45,6
45,5
45,6
42,7
48,4
45,5
45,5
45,5
45,5(ICDs) is cost-effective. QALY, quality adjusted life year.
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816 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 2 – 8 1 7(IQWiG) in Germany was mandated to evaluate the relationship
between costs and effects of drugs and other technologies. The
first cost-effectiveness assessments have just started and results
are expected in late 2011. The purpose is to identify drugs (tech-
nologies) that are not efficient at the current price. To this end,
IQWiG uses a decision criterion that states that the ICER of a new
drug (technology) compared with the next effective intervention
should not be higher than that of the next effective intervention
compared to its next effective intervention [33]. That is, the
threshold ICER is specific for each therapeutic area and not uni-
form. According to this decision criterion, the threshold ICER for
ICD implantation should equal the ICER of conventional therapy
(i.e., the comparator of ICD implantation) compared to its compar-
ator. That is, we would need to compare the set of medications
used for conventional therapy in MADIT II with perhaps a smaller
set of medications (the comparator’s comparator). Still, we note
that although IQWiGbuilds on a cost-effectiveness assessment, its
goal is to define a ceiling price for the technology considered. This
is somewhat different from the purpose of our analysis.
Calculation of QALYs is not neutral regarding whose life is ex-
tended: a person with disability obtains fewer QALYs from life
extension than a person in perfect health. This has been criticized
based on ethical grounds [34]. If we instead use life years as a
measure of outcome (i.e., disregard disabilities in added life years),
cost-effectiveness improves yet still remains higher than formany
well-accepted interventions.
Yet even if ICD therapy is still considered cost-effective, annual
costs of more than €1.7 billion, which would translate into a 1.0%
increase of the total SHI budget (€161 billion [35]), are concerning.
The reason is the high incidence of heart failure after MI affecting
perhaps 50,000 Germans annually. Adopting a societal perspective
would further increase the ICER and total population cost of ICD
therapy. The reason is that a societal perspective also considers
nursing costs during added years of life, costs of hospital infra-
structure (building and equipment maintenance), which are paid
by the states, and copayments.
Results of our analysis should be interpreted with caution as
ourmodel is far from being perfect, but inmodelling studies this is
rarely the case due to constraints of resources, time, and informa-
tion availability. Cost-effectiveness of ICDs may be underesti-
mated (i.e., the ICERmay be overestimated) because ourmodel did
not consider that costs of the expensive last year of life decrease
with age due to less aggressive care. Hence, there are savings as-
sociatedwith extending life [36]. On the other hand, cost-effective-
ness of ICDs may be overestimated as complications rates associ-
ated with ICD implantation vary by physician and may be higher
outside the trial (MADIT II) setting [37]. Furthermore, theremay be
decline in quality of life with age, thus leading to a decrease in
he number of QALYs gained. Yet, the univariate sensitivity anal-
sis on quality of life (Table 3) suggests that a potential decline is
nlikely to have a major impact on the ICER of ICD implantation.
inally, the population cost analysis was based on an average age
f 64 years at the time of ICD implantation. Higher age leads to
ower survival [38] and lower lifetime costs. The reverse may be
rue for lower age.
Results of our analysis are not transferable to other countries
ecause differences in ICD prices, mortality due to unrelated dis-
ases, and disutility from heart failure exist. For the same reasons
esults are not comparable to previously published international
EAs. In addition, previous CEAs—even those only based on
ADIT II data (e.g., references 7 and 8)—are not based on long-
erm data across 8 years.
In the future cost-effectiveness of ICD therapymay improve for
everal reasons. First, battery life may increase. Second, ICD im-
rovement could lead to fewer inappropriate shocks and hence
otentially improve quality of life compared to conventional ther-apy. And third, homemonitoring of ICD patients could reduce the
number of patient visits and thus outpatient costs.
If policy makers decide to reimburse ICDs in the MADIT-II pop-
ulation, they will need to either increase their budget by raising
premiums or abandon coverage for other currently funded medi-
cal interventions. Alternatively, subgroups with better cost-effec-
tiveness need to be identified. For example, MADIT-II patients
whose ICDs were programmed to provide low right-ventricular
pacing have had lowest mortality rates [39] and thus may also
have a lower ICER.
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